Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Mahesh PA, Zheng Y, Zhao R, Li S, Manogaran P, Fan R, Nikolenko VN, Wen H, Basappa B, Liu J. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health 2024;14:04155. This study provides an overview of the global burden of gynaecological cancers (GCs) in 2022 and projections to 2050. In 2022, there were 1,473,427 new GC cases and 680,372 deaths globally. The age-standardised incidence rate (ASIR) was 30.3 per 100,000, and the age-standardised mortality rate (ASMR) was 13.2 per 100,000. The highest incidence rates were observed in Eastern Africa (ASIR of 50.7 per 100,000) and the lowest in Australia and New Zealand (ASIR of 8.1 per 100,000). The highest mortality rates were in Eastern Africa (ASMR of 35.3 per 100,000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100,000). Eswatini had the highest incidence and mortality rates (105.4 and 71.1 per 100,000, respectively), while Yemen had the lowest (5.8 and 4.4 per 100,000, respectively). The study also highlights the significant regional disparities in GC incidence and mortality, with high HDI countries having the highest incidence rates and low HDI countries having the second highest. The study projects that the number of new GC cases and deaths will increase significantly by 2050, with Eastern Africa, Middle Africa, Northern Africa, Western Africa, Western Asia, and Melanesia experiencing the highest increases. The study also emphasizes the importance of early screening and prevention strategies to reduce the burden of GCs. The findings highlight the need for improved healthcare infrastructure, increased access to screening and treatment, and the implementation of effective prevention strategies to reduce the global burden of GCs.Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Mahesh PA, Zheng Y, Zhao R, Li S, Manogaran P, Fan R, Nikolenko VN, Wen H, Basappa B, Liu J. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health 2024;14:04155. This study provides an overview of the global burden of gynaecological cancers (GCs) in 2022 and projections to 2050. In 2022, there were 1,473,427 new GC cases and 680,372 deaths globally. The age-standardised incidence rate (ASIR) was 30.3 per 100,000, and the age-standardised mortality rate (ASMR) was 13.2 per 100,000. The highest incidence rates were observed in Eastern Africa (ASIR of 50.7 per 100,000) and the lowest in Australia and New Zealand (ASIR of 8.1 per 100,000). The highest mortality rates were in Eastern Africa (ASMR of 35.3 per 100,000) and the lowest in Australia and New Zealand (ASMR of 8.1 per 100,000). Eswatini had the highest incidence and mortality rates (105.4 and 71.1 per 100,000, respectively), while Yemen had the lowest (5.8 and 4.4 per 100,000, respectively). The study also highlights the significant regional disparities in GC incidence and mortality, with high HDI countries having the highest incidence rates and low HDI countries having the second highest. The study projects that the number of new GC cases and deaths will increase significantly by 2050, with Eastern Africa, Middle Africa, Northern Africa, Western Africa, Western Asia, and Melanesia experiencing the highest increases. The study also emphasizes the importance of early screening and prevention strategies to reduce the burden of GCs. The findings highlight the need for improved healthcare infrastructure, increased access to screening and treatment, and the implementation of effective prevention strategies to reduce the global burden of GCs.